Brief: Exicure Presents Interim Results From Ongoing Phase 1B/2 Trial Of Cavrotolimod

Exicure

16/09/2020 12:30

Sept 16 (Reuters) - Exicure Inc  XCUR.O :
    * EXICURE PRESENTS PROMISING INTERIM RESULTS FROM ONGOING
PHASE
1B/2 TRIAL OF CAVROTOLIMOD AT VIRTUAL KOL EVENT TODAY
    * EXICURE INC - CONFIRMED ORR 21% (4/19 PATIENTS) OVERALL IN
PHASE
1B DOSE-ESCALATION STAGE OF CAVROTOLIMOD
    * EXICURE - MEDIAN DURATION OF RESPONSE NOT BEEN REACHED AS
ALL 4
CONFIRMED RESPONDERS NOT PROGRESSED AFTER 11 MONTHS MEDIAN
FOLLOW-UP IN CAVROTOLIMOD TRIAL
    * EXICURE - CONTINUES TO OBSERVE CAVROTOLIMOD IS WELL
TOLERATED
WITH 98% OF ALL TREATMENT-EMERGENT ADVERSE EVENTS ASSESSED AS
GRADE 1 OR 2 IN SEVERITY
    * EXICURE INC - NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS
WERE
REPORTED TO DATE IN  CAVROTOLIMOD TRIAL
    * EXICURE INC - EXPECTS TO PROVIDE INTERIM ORR RESULTS FROM
MCC
AND CSCC COHORTS OF PHASE 2 PORTION OF CLINICAL TRIAL IN FIRST
HALF OF 2021
    * EXICURE INC - EXPECTS TO PROVIDE FINAL ORR RESULTS FROM
MCC AND
CSCC COHORTS OF PHASE 2 PORTION OF CLINICAL TRIAL BY YEAR END
2021

Source text for Eikon:  ID:nBw3sms88a 
Further company coverage:  XCUR.O 

 ((Reuters.Briefs@thomsonreuters.com;))